Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis

Blood Cancer J. 2015 Oct 16;5(10):e360. doi: 10.1038/bcj.2015.90.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Calreticulin / genetics*
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Mutation*
  • Primary Myelofibrosis / genetics*
  • Primary Myelofibrosis / mortality
  • Prognosis
  • Young Adult

Substances

  • CALR protein, human
  • Calreticulin